2022
Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTestingGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer risk
2015
Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.Peer-Reviewed Original ResearchConceptsClinical trialsRisk groupsHuman papillomavirus-associated oropharynx cancerHPV-negative OPCPoor-risk subsetTreatment-related morbidityDe-escalation trialsPrognostic risk groupsClinical trial optionsYounger median ageNew treatment strategiesIdeal patient groupNovel therapeutic targetInvasive surgical techniquesDeintensification trialsTreatment deintensificationOropharynx cancerSmoking exposureMetastatic diseaseModality therapyFavorable prognosisMedian ageBetter prognosisSuperior prognosisIntense therapy
2010
Review: Castration-resistant prostate cancer: new science and therapeutic prospects
Bellmunt J, Oh W. Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances In Medical Oncology 2010, 2: 189-207. PMID: 21789134, PMCID: PMC3126017, DOI: 10.1177/1758834009359769.Peer-Reviewed Original ResearchCastration-resistant prostate cancerAndrogen receptorCastration-resistant prostate cancer treatmentTherapies targeting different pathwaysGonadotropin-releasing hormone therapyCastration-resistant prostate cancer tissuesLigand-activated androgen receptorAgents targeting angiogenesisImprove patient selectionLate-stage clinical testingManagement of patientsClinical trial optionsPatient management strategiesMDV-3100Sipuleucel-THormone therapyProstate cancerPatient selectionOral compoundsPatient populationAndrogen levelsPatientsClinical testingTrial optionsTrial design
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply